Tests a low-dose chemotherapy combination in metastatic pancreatic cancer

Trial details

Who runs it

National Cancer Centre, Singapore

Trial code

NCT05929885

Record updated

23 June 2026

Original description

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.Read full original descriptionShow less

A Phase II Study of Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients.

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.

The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in patients with advanced PDAC and will lead to a favourable response rate.

Patients will be prospectively enrolled in two stages - In stage 1, patients will be recruited and evaluated for response and toxicity. In stage 2, more patients will be recruited for further evaluation of response and toxicity.

Inclusion: The patient must meet all of the inclusion criteria to participate in the study; Aged above 21; Histopathological diagnosis of pancreatic cancer; Advanced disease not amenable to curative resection (locally advanced or metastatic disease); Measureable disease by RECIST 1.1 criteria; Life expectancy of at least 12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; Adequate hematologic function (granulocyte count ≥ 1.5 × 10**9/L, platelet count ≥ 100 × 10**9/L),; Adequate hepatic function (total bilirubin ≤ 1.5 x the upper limits of normal [ULN], AST and ALT, ALP ≤ 3 x ULN or < 5 x ULN in case of hepatic involvement),; Adequate renal function (creatinine clearance > 50 mL/min) will be eligible for inclusion into the study; Able to provide written and informed consent.

Exclusion: Concurrent illness, including severe infection, that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety; Treatment with palliative chemotherapy or radiotherapy within 4 weeks prior to enrolment into the study; Major surgery within two weeks prior to enrolment into the study; Patients on chronic immunosuppressive therapy; Patients on anticoagulant therapy with vitamin K antagonists; History of another malignancy within 5 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free after definitive primary treatment for at least 5 years; Untreated CNS metastases or leptomeningeal disease. Patients with brain metastases that have been treated, and are asymptomatic, and have been stable for 3 or more months after treatment are allowed. A baseline CT or MRI brain is only required if there is clinical suspicion of CNS involvement; Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol; Any patient meeting any of the exclusion criteria at baseline will be excluded from participation; Pregnancy, lactation or inadequate contraception. Women of childbearing potential must have a negative pregnancy test within 3 days of enrolment and agree to use a reliable means of contraception. Men must have been surgically sterilised or agree to use a barrier method of contraception.

ClinicalTrials.gov NCT05929885